Screener
MaxCyte MXCT Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Assay And Other Service Revenue | $583K+88.1% | $482K+21.4% | $609K— | $650K+56.3% | $310K+35.4% | |
| License | $2.59M-11.5% | $5.53M+18.2% | $2.54M-3.8% | $2.23M-12.8% | $2.93M-46.4% | |
| Revenue by Geography | ||||||
| Non Us | $2.64M-17.3% | $3.04M+28.8% | $3.41M+1.0% | $2.99M-0.9% | $3.19M+1.7% | |
| US | $4.63M-12.9% | $6.62M-17.6% | $3.89M-26.8% | $3.84M-25.4% | $5.31M-27.1% |
FAQ
- How does MaxCyte break its business down?
- MaxCyte (MXCT) reports revenue by product across 2 parts — Assay And Other Service Revenue and License. Each is extracted from the segment footnotes and tracked over time.
- Where does MaxCyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MaxCyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
